RxDoctor Payments Data

Garland Berry, MD

Ophthalmology · Carrollton, GANPI 1275597296

Payments from drug & device makers

$3,028in general payments, 2019–2025

Across 96 payments — averaging $31.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • AbbVie$385
  • Amgen$247
  • Glaukos Corporation$172
  • Oyster Point Pharma, Inc.$135
  • Dompe US, Inc.$91
  • plus $526 from 14 others

What the payments were for

  • Travel & lodging$64221%
  • Food & beverage$2,38779%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,028 in reported general payments places this provider in the 60th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$515,518
Medicare patients
1,208
Services billed
4,375

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost101$45,737
XiidraLifitegrast19$26,307
RestasisCyclosporine19$21,632
Cyclosporine16$13,798
Latanoprost818$12,472
CombiganBrimonidine Tartrate/Timolol24$9,366
RocklatanNetarsudil Mesylat/Latanoprost24$8,722
Alphagan PBrimonidine Tartrate14$7,249
Travoprost25$4,319
Brimonidine Tartrate79$4,179
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat159$2,617
Prednisolone Acetate48$2,272
Timolol Maleate205$2,062
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol12$1,972
Dorzolamide Hcl86$1,059

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$385$83,984158 claims
Bausch & Lomb Americas Inc.Xiidra$36$26,30719 claims
Aerie Pharmaceuticals, Inc.Rocklatan$28$8,72224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Carrollton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →